Pani Michael A, Regulla Karoline, Segni Maria, Krause Maren, Hofmann Stefan, Hufner Michael, Herwig Jurgen, Pasquino Anna Maria, Usadel Klaus-H, Badenhoop Klaus
Department of Internal Medicine I, Division of Endocrinology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Eur J Endocrinol. 2002 Jun;146(6):777-81. doi: 10.1530/eje.0.1460777.
The vitamin D endocrine system plays a role in the regulation of (auto)immunity and cell proliferation. Vitamin D 1alpha-hydroxylase (CYP1alpha) is one of the key enzymes regulating both systemic and tissue levels of 1,25-dihyroxyvitamin D(3) (1,25(OH)(2)D(3)). Administration of 1,25(OH)(2)D(3), whose serum levels were found to be reduced in type 1 diabetes and thyroid autoimmunity, prevents these diseases in animal models. We therefore investigated a recently reported CYP1alpha polymorphism for an association with type 1 diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
Four hundred and seven Caucasian pedigrees with one offspring affected by either type 1 diabetes (209 families), Graves' disease (92 families) or Hashimoto's thyroiditis (106 families) were genotyped for a C/T polymorphism in intron 6 of the CYP1alpha gene on chromosome 12q13.1-13.3 and transmission disequilibrium testing (TDT) was performed. Subsets of affected offspring stratified for HLA-DQ haplotype were compared using chi(2) testing.
There was no deviation from the expected transmission frequency in either type 1 diabetes mellitus (P=0.825), Graves' disease (P=0.909) or Hashimoto's thyroiditis (P=0.204). However, in Hashimoto's thyroiditis the CYP1alpha C allele was significantly more often transmitted to HLA-DQ2(-) patients (27 transmitted vs 14 not transmitted; TDT: P=0.042) than expected. The C allele was less often transmitted to HLA-DQ2(+) patients (9 transmitted vs 12 not transmitted; TDT: P=0.513), although the difference was not significant (chi(2) test: P=0.143). A similar difference was observed in type 1 diabetes between offspring with high and low risk HLA-DQ haplotypes (chi(2) test: P=0.095).
The CYP1alpha intron 6 polymorphism appears not to be associated with type 1 diabetes mellitus, Graves' disease and Hashimoto's thyroiditis. A potential association in subsets of patients with type 1 diabetes and Hashimoto's thyroiditis should be further investigated as well as its functional implications.
维生素D内分泌系统在(自身)免疫调节和细胞增殖中发挥作用。维生素D 1α-羟化酶(CYP1α)是调节1,25-二羟维生素D3(1,25(OH)2D3)全身和组织水平的关键酶之一。1,25(OH)2D3的血清水平在1型糖尿病和甲状腺自身免疫性疾病中降低,在动物模型中给予该物质可预防这些疾病。因此,我们研究了最近报道的CYP1α基因多态性与1型糖尿病、格雷夫斯病和桥本甲状腺炎之间的关联。
对407个白种人家系进行基因分型,这些家系中有一个后代患有1型糖尿病(209个家系)、格雷夫斯病(92个家系)或桥本甲状腺炎(106个家系),检测位于12号染色体q13.1 - 13.3上CYP1α基因第6内含子的C/T多态性,并进行传递不平衡检验(TDT)。使用卡方检验比较按HLA - DQ单倍型分层的患病后代子集。
在1型糖尿病(P = 0.825)、格雷夫斯病(P = 0.909)或桥本甲状腺炎(P = 0.204)中,均未发现与预期传递频率有偏差。然而,在桥本甲状腺炎中,CYP1α C等位基因传递给HLA - DQ2(-)患者的频率(传递27例,未传递14例;TDT:P = 0.042)显著高于预期。C等位基因传递给HLA - DQ2(+)患者的频率较低(传递9例,未传递12例;TDT:P = 0.513),尽管差异不显著(卡方检验:P = 0.143)。在1型糖尿病中,高风险和低风险HLA - DQ单倍型的后代之间也观察到类似差异(卡方检验:P = 0.095)。
CYP1α基因第6内含子多态性似乎与1型糖尿病、格雷夫斯病和桥本甲状腺炎无关。1型糖尿病和桥本甲状腺炎患者亚组中的潜在关联及其功能意义应进一步研究。